ArticleEJNMMI research2018
Which is the proper reference tissue for measuring the change in FDG PET metabolic volume of cardiac sarcoidosis before and after steroid therapy?
Article in EJNMMI research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Visual analysis of [European journal of nuclear medicine and molecular imaging · 2026Article
- Strict carbohydrate restriction enables volume-based FDG-PET/CT to outperform SUVmax for risk stratification in cardiac sarcoidosis.International journal of cardiology. Heart & vasculature · 2026Article
- Article
- Article
- Hypo-segmentation ofEJNMMI research · 2025Article
- Use of 18F-FDG PET in assessing response to treatment in adults with pulmonary sarcoidosis: A systematic literature review.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- Myocardial-to-background ratio in F18-fluorodeoxyglucose PET in cardiac sarcoidosis for diagnosis and evaluation of therapeutic response.International journal of cardiology. Heart & vasculature · 2025Article
- Prednisone vs methotrexate in treatment naïve cardiac sarcoidosis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Hot spot imaging in cardiovascular diseases: an information statement from SNMMI, ASNC, and EANM.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Reproducibility of [18F]FDG PET/CT liver SUV as reference or normalisation factor.European journal of nuclear medicine and molecular imaging · 2023Article
- Intrapatient variability of 18F-FDG uptake in normal tissues.Journal of clinical imaging science · 2022Article
- Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
- The Role of Multimodality Imaging in Cardiac Sarcoidosis.Korean circulation journal · 2021Review
- Clinical Features and Diagnosis of Cardiac Sarcoidosis.Journal of clinical medicine · 2021Review
- Clinical implications of increased uptake in bone marrow and spleen on FDG-PET in patients with bacteremia.European journal of nuclear medicine and molecular imaging · 2021Article
- Quantitative FDG PET Assessment for Oncology Therapy.Cancers · 2021Review
- The role of positron emission tomography in the assessment of cardiac sarcoidosis.The British journal of radiology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiac sarcoidosis (CS) is a rare but potentially life-threatening disease that causes conduction disturbance, systolic dysfunction, and, most notably, sudden cardiac death.
resultsThe SUVmax, SUVmean, and SUVpeak of the liver during steroid therapy significantly increased from the time point before the therapy (SUVmax 3.5 ± 0.4 vs. 3.8 ± 0.6, p = 0.014; SUVmean 2.7 ± 0.3 vs. 3.0 ± 0.5, p = 0.0065; SUVpeak 3.0 ± 0.4 vs. 3.4 ± 0.6, p = 0.006). However, the SUVmax, SUVmean, and SUVpeak in the DA did not significantly change (SUVmax 2.2 ± 0.3 vs. 2.2 ± 0.4, p = 0.46; SUVmean 1.9 ± 0.3 vs. 2.0 ± 0.4, p = 0.56; SUVpeak 2.0 ± 0.3 vs. 2.0 ± 0.3, p = 0.70).
conclusionsWe measured FDG uptake in the liver and blood pool before and during steroid therapy. Steroid therapy increased the liver uptake but not the blood pool uptake. Our findings suggested that the DA uptake is a more suitable threshold than liver uptake to evaluate therapeutic effects using volume-based analysis of cardiac FDG PET.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.